vs
Sotera Health Co（SHC）とVIEMED HEALTHCARE, INC.（VMD）の財務データ比較。上の社名をクリックして会社を切り替えられます
Sotera Health Coの直近四半期売上が大きい（$303.4M vs $76.2M、VIEMED HEALTHCARE, INC.の約4.0倍）。Sotera Health Coの純利益率が高く（11.5% vs 7.4%、差は4.1%）。VIEMED HEALTHCARE, INC.の前年同期比売上増加率が高い（25.5% vs 4.6%）。Sotera Health Coの直近四半期フリーキャッシュフローが多い（$52.4M vs $9.7M）。過去8四半期でVIEMED HEALTHCARE, INC.の売上複合成長率が高い（22.7% vs 10.6%）
Sotera Health Coは医療安全ソリューションをグローバルに提供する企業で、医療機器メーカー、製薬会社、食品・消費財企業を対象に滅菌サービス、分析検査、規制対応コンサルティングを提供し、顧客の製品安全性確保と基準準拠を支援しています。
Viemed Healthcare, Inc.は呼吸ケアソリューションを専門とする医療テクノロジー企業で、携帯型人工呼吸器、呼吸療法機器および関連支援サービスを開発・製造・販売し、北米、欧州、アジア太平洋の急性期ケア、回復期ケア、在宅ケア分野で事業を展開しています。
SHC vs VMD — 直接比較
損益計算書 — Q4 2025 vs Q4 2025
| 指標 | | |
|---|---|---|
| 売上 | $303.4M | $76.2M |
| 純利益 | $34.8M | $5.6M |
| 粗利率 | 54.7% | 57.9% |
| 営業利益率 | 23.2% | 11.0% |
| 純利益率 | 11.5% | 7.4% |
| 売上前年比 | 4.6% | 25.5% |
| 純利益前年比 | 182.8% | 30.7% |
| EPS（希薄化後） | $0.12 | $0.14 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $303.4M | $76.2M | ||
| Q3 25 | $311.3M | $71.9M | ||
| Q2 25 | $294.3M | $63.1M | ||
| Q1 25 | $254.5M | $59.1M | ||
| Q4 24 | $290.2M | $60.7M | ||
| Q3 24 | $285.5M | $58.0M | ||
| Q2 24 | $276.6M | $55.0M | ||
| Q1 24 | $248.2M | $50.6M |
| Q4 25 | $34.8M | $5.6M | ||
| Q3 25 | $48.4M | $3.5M | ||
| Q2 25 | $8.0M | $3.2M | ||
| Q1 25 | $-13.3M | $2.6M | ||
| Q4 24 | $12.3M | $4.3M | ||
| Q3 24 | $17.0M | $3.9M | ||
| Q2 24 | $8.8M | $1.5M | ||
| Q1 24 | $6.3M | $1.6M |
| Q4 25 | 54.7% | 57.9% | ||
| Q3 25 | 57.0% | 57.5% | ||
| Q2 25 | 56.6% | 58.3% | ||
| Q1 25 | 53.2% | 56.3% | ||
| Q4 24 | 56.6% | 59.5% | ||
| Q3 24 | 55.4% | 59.3% | ||
| Q2 24 | 55.2% | 59.8% | ||
| Q1 24 | 51.2% | 58.9% |
| Q4 25 | 23.2% | 11.0% | ||
| Q3 25 | 23.4% | 7.8% | ||
| Q2 25 | 6.4% | 8.1% | ||
| Q1 25 | -5.8% | 6.5% | ||
| Q4 24 | 30.0% | 10.6% | ||
| Q3 24 | 28.2% | 9.7% | ||
| Q2 24 | 27.8% | 6.6% | ||
| Q1 24 | 21.4% | 4.4% |
| Q4 25 | 11.5% | 7.4% | ||
| Q3 25 | 15.5% | 4.9% | ||
| Q2 25 | 2.7% | 5.0% | ||
| Q1 25 | -5.2% | 4.4% | ||
| Q4 24 | 4.2% | 7.1% | ||
| Q3 24 | 6.0% | 6.7% | ||
| Q2 24 | 3.2% | 2.7% | ||
| Q1 24 | 2.5% | 3.2% |
| Q4 25 | $0.12 | $0.14 | ||
| Q3 25 | $0.17 | $0.09 | ||
| Q2 25 | $0.03 | $0.08 | ||
| Q1 25 | $-0.05 | $0.06 | ||
| Q4 24 | $0.05 | $0.10 | ||
| Q3 24 | $0.06 | $0.10 | ||
| Q2 24 | $0.03 | $0.04 | ||
| Q1 24 | $0.02 | $0.04 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $344.6M | $13.5M |
| 総負債低いほど良い | $2.1B | — |
| 株主資本純資産 | $606.0M | $141.5M |
| 総資産 | $3.3B | $199.2M |
| 負債/資本比率低いほどレバレッジが低い | 3.53× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $344.6M | $13.5M | ||
| Q3 25 | $299.2M | $11.1M | ||
| Q2 25 | $332.4M | $20.0M | ||
| Q1 25 | $304.4M | $10.2M | ||
| Q4 24 | $277.2M | $17.5M | ||
| Q3 24 | $306.7M | $11.3M | ||
| Q2 24 | $246.1M | $8.8M | ||
| Q1 24 | $261.1M | $7.3M |
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $2.2B | — |
| Q4 25 | $606.0M | $141.5M | ||
| Q3 25 | $550.5M | $133.6M | ||
| Q2 25 | $511.3M | $139.7M | ||
| Q1 25 | $414.1M | $134.8M | ||
| Q4 24 | $404.9M | $131.4M | ||
| Q3 24 | $470.2M | $125.0M | ||
| Q2 24 | $422.8M | $119.4M | ||
| Q1 24 | $429.4M | $116.3M |
| Q4 25 | $3.3B | $199.2M | ||
| Q3 25 | $3.2B | $202.4M | ||
| Q2 25 | $3.2B | $184.6M | ||
| Q1 25 | $3.1B | $178.1M | ||
| Q4 24 | $3.1B | $177.1M | ||
| Q3 24 | $3.1B | $169.5M | ||
| Q2 24 | $3.1B | $163.9M | ||
| Q1 24 | $3.1B | $154.9M |
| Q4 25 | 3.53× | — | ||
| Q3 25 | 3.89× | — | ||
| Q2 25 | 4.34× | — | ||
| Q1 25 | 5.36× | — | ||
| Q4 24 | 5.49× | — | ||
| Q3 24 | 4.73× | — | ||
| Q2 24 | 5.26× | — | ||
| Q1 24 | 5.19× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $103.1M | $18.4M |
| フリーキャッシュフロー営業CF - 設備投資 | $52.4M | $9.7M |
| FCFマージンFCF / 売上 | 17.3% | 12.7% |
| 設備投資強度設備投資 / 売上 | 16.7% | 11.5% |
| キャッシュ転換率営業CF / 純利益 | 2.96× | 3.27× |
| 直近12ヶ月FCF直近4四半期 | $149.2M | $11.9M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $103.1M | $18.4M | ||
| Q3 25 | $71.2M | $18.4M | ||
| Q2 25 | $57.4M | $12.3M | ||
| Q1 25 | $55.5M | $2.9M | ||
| Q4 24 | $55.7M | $15.0M | ||
| Q3 24 | $97.5M | $12.7M | ||
| Q2 24 | $61.3M | $10.2M | ||
| Q1 24 | $9.7M | $1.2M |
| Q4 25 | $52.4M | $9.7M | ||
| Q3 25 | $35.0M | $10.7M | ||
| Q2 25 | $26.2M | $4.1M | ||
| Q1 25 | $35.6M | $-12.6M | ||
| Q4 24 | $-10.2M | $3.2M | ||
| Q3 24 | $61.1M | $1.7M | ||
| Q2 24 | $19.4M | $1.2M | ||
| Q1 24 | $-25.2M | $-4.8M |
| Q4 25 | 17.3% | 12.7% | ||
| Q3 25 | 11.2% | 14.9% | ||
| Q2 25 | 8.9% | 6.5% | ||
| Q1 25 | 14.0% | -21.4% | ||
| Q4 24 | -3.5% | 5.2% | ||
| Q3 24 | 21.4% | 3.0% | ||
| Q2 24 | 7.0% | 2.3% | ||
| Q1 24 | -10.2% | -9.5% |
| Q4 25 | 16.7% | 11.5% | ||
| Q3 25 | 11.6% | 10.6% | ||
| Q2 25 | 10.6% | 12.9% | ||
| Q1 25 | 7.8% | 26.2% | ||
| Q4 24 | 22.7% | 19.5% | ||
| Q3 24 | 12.7% | 19.0% | ||
| Q2 24 | 15.2% | 16.3% | ||
| Q1 24 | 14.1% | 11.9% |
| Q4 25 | 2.96× | 3.27× | ||
| Q3 25 | 1.47× | 5.23× | ||
| Q2 25 | 7.21× | 3.88× | ||
| Q1 25 | — | 1.09× | ||
| Q4 24 | 4.52× | 3.47× | ||
| Q3 24 | 5.73× | 3.29× | ||
| Q2 24 | 7.00× | 6.94× | ||
| Q1 24 | 1.53× | 0.73× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
SHC
| Transferred At Point In Time | $198.4M | 65% |
| Nelson Labs | $55.2M | 18% |
| Nordion | $49.8M | 16% |
VMD
セグメントデータなし
